Status:
UNKNOWN
Assessment of Progranulin and FAM19A5 Protein Blood Levels in Metabolic Syndrome
Lead Sponsor:
Poznan University of Medical Sciences
Conditions:
Nutrition Disorders
Hypertension
Eligibility:
All Genders
18-99 years
Brief Summary
The main objective of the study is to assess the serum levels of progranulin and FAM19A5 protein in adults with metabolic syndrome.
Detailed Description
The study is planned to be conducted on 40 adults with metabolic syndrome. As a control, it is planned to recruit 40 adults without metabolic syndrome. From all participants fasting venous blood sampl...
Eligibility Criteria
Inclusion
- written and informed consent of the participant to participate in the study;
- age 18-99;
- meeting at least three of the following five metabolic syndrome criteria:
- waist circumference ≥80 cm in women and ≥94 cm in men;
- serum triglycerides\> 150 mg / dl (1.7 mmol / l) or treatment of hypertriglyceridemia;
- HDL serum concentration \<50 mg / dl (1.3 mmol / l) - in women and \<40 mg / dl (1.0 mmol / l) - in men or treatment of this lipid disorder;
- systolic blood pressure ≥ 130 mm Hg or diastolic blood pressure ≥ 85 mm Hg, or treatment of previously diagnosed hypertension;
- fasting plasma glucose ≥100 mg / dl (5.6 mmol / l) or pharmacological treatment of type 2 diabetes.
Exclusion
- secondary form obesity,
- substitution of progranulin or / and FAM19A5 protein,
- weight reduction above 5% of baseline body weight in the last 3 months preceding recruitment,
- liposuction and / or other fat reduction treatments,
- pacemaker, cardioverter / defibrillator,
- condition after stroke,
- Alzheimer's disease,
- fronto-temporal dementia,
- occurrence of other neurodegenerative diseases,
- occurrence of significant neurological disorders,
- occurrence of inflammatory autoimmune diseases,
- lysosomal storage diseases,
- clinically significant abnormal liver, kidney or thyroid function;
- acute or clinically significant inflammatory process in the respiratory, digestive, genitourinary tracts,
- connective tissue diseases or arthritis;
- active cancer,
- addiction to alcohol or drugs;
- pregnancy or childbirth during recruitment or 3 months before recruitment;
- current lactation or lactation within 3 months before recruitment;
- and / or any other condition which, according to researchers, would cause that participation would not be in the patient's best interest or could limit the credibility of the study
Key Trial Info
Start Date :
July 3 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04451616
Start Date
July 3 2020
End Date
June 1 2021
Last Update
August 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences
Poznan, Wielkopolska, Poland, 60-569